CDK9-IN-16 (CAS: )
Background Information of CDK9-IN-16
CDK9-IN-16 (Compound 21) is a highly selective and potent CDK9 kinase inhibitor with an IC50 of 0.002±0.0002 μM. CDK9 is a key regulator of transcription elongation in eukaryotic cells and has been considered as a potential drug target for several diseases including cardiac hypertrophy and certain cancers such as a variety of blood cancers as well as solid tumors.
Storage Condition of CDK9-IN-16
Quality Control and Spectral Data
Mechanism and Indications
||Sponsor & Collaborators
Structure Information of CDK9-IN-16
||[[email protected]@H]1(NC2=NC=C(Cl)C(C3=CSC(NCC4CCOCC4)=N3)=C2)CC[[email protected]@H](NCCOC)CC1 |&1:0,24|
Other Form Products of CDK9-IN-16
Recommended Products in Same Target
Recommended Products in the Same Indication
Safety Data of CDK9-IN-16
Chemical and Physical Properties
.Beilei Wang, et al. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. Eur J Med Chem. 13 September 2018.
Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and C-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.